SS
ARQT icon

Steve Schonfeld’s Arcutis Biotherapeutics ARQT Stock Holding History

Steve Schonfeld’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-189,555
Closed -$3.57M – 2040
2025
Q3 		$3.57M Sell
189,555
-330,729
-64% -$5.22M 0.02% 748
2025
Q2 		$7.29M Buy
520,284
+501,818
+2,718% +$7.03M 0.05% 439
2025
Q1 		$289K Sell
18,466
-4,534
-20% -$63.9K ﹤0.01% 1808
2024
Q4 		$320K Sell
23,000
-7,349
-24% -$80.5K ﹤0.01% 1589
2024
Q3 		$282K Buy
30,349
+14,175
+88% +$140K ﹤0.01% 1679
2024
Q2 		$150K Buy
+16,174
New +$146K ﹤0.01% 1848
2023
Q1 		– Sell
-28,100
Closed -$416K – 2085
2022
Q4 		$416K Buy
+28,100
New +$491K ﹤0.01% 1627
2022
Q2 		– Sell
-17,996
Closed -$347K – 2514
2022
Q1 		$347K Buy
+17,996
New +$304K ﹤0.01% 1596

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Steve Schonfeld's ARQT Position: Q4 2025 in Review

Steve Schonfeld sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 189,555 shares — an estimated $3.57M sold.

Steve Schonfeld first reported a position in ARQT in Q1 2022 and held it in 8 quarters. The position peaked at $7.29M in Q2 2025. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Steve Schonfeld reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Steve Schonfeld sold 189,555 Arcutis Biotherapeutics shares in Q4 2025, an estimated $3.57M.
  • Steve Schonfeld first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 8 quarters.
  • Steve Schonfeld's Arcutis Biotherapeutics position peaked at $7.29M in Q2 2025.
  • 283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.